Cure rates by patient observation (all UI types) ‐ not reported · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement rates by patient observation (all UI types) ‐ not reported · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Condition‐specific quality of life ICIQ Overactive Bladder Symptoms Quality of Life. Scale from: 25 to 160. Better quality of life indicated by lower values. · adults with urinary incontinence
1 finding from 1 review
Adverse effects ‐ not reported · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cure rates by symptom quantification (all UI types) ‐ not reported · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement rates by symptom quantification (all UI types) ‐ not reported · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of incontinent episodes · adults with urinary incontinence
1 finding from 1 review
Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines№ of participants: 30(1 RCT) · preterm infants
It is very uncertain whether caffeine changes side effects (tachycardia, agitation, or feed intolerance) leading… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.17 [0.02, 1.32]
Studies not reported
Very low
Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants with or at risk for apnea of prematurity
It is very uncertain whether high‐dose changes side effects (tachycardia, agitation or feed intolerance) leading to… compared with standard‐dose strategies (very low certainty).
3 findings from 1 review
Failed apnea reduction · treatment of apnea
Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
3 findings from 1 review
RR 0.45 [0.2, 1.05]
1 study · 21 participants
Low
RR 1.35 [0.53, 3.45]
4 studies · 84 participants
Very low
RR 0.08 [0.01, 1.17]
1 study · 10 participants
Very low
2a. Failed apnea reduction after 2–7 days – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
2b. Failed apnea reduction after 2–7 days – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
It is very uncertain whether doxapram changes 2b. Failed apnea reduction after 2–7 days – doxapram compared to… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
1 finding from 1 review
2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
Doxapram showed no clear difference in 2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients with loss or gain of hearing/reduction in progression of hearing loss · adults with Ménière's disease or syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Proportion of patients with a reduction in the severity of tinnitus · adults with Ménière's disease or syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Proportion of patients with a reduction in the perception of aural fullness · adults with Ménière's disease or syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found